Skip to content

Booksellers & Trade Customers: Sign up for online bulk buying at trade.atlanticbooks.com for wholesale discounts

Booksellers: Create Account on our B2B Portal for wholesale discounts

Optimization of Pharmaceutical R&d Programs and Portfolios: Design and Investment Strategy

by Zoran Antonijevic
Save 35% Save 35%
Current price ₹13,221.00
Original price ₹20,339.00
Original price ₹20,339.00
Original price ₹20,339.00
(-35%)
₹13,221.00
Current price ₹13,221.00

Imported Edition - Ships in 12-14 Days

Free Shipping in India on orders above Rs. 500

Request Bulk Quantity Quote
+91
Book cover type: Paperback
  • ISBN13: 9783319343129
  • Binding: Paperback
  • Subject: N/A
  • Publisher: Springer
  • Publisher Imprint: Springer
  • Publication Date:
  • Pages: 202
  • Original Price: EUR 179.99
  • Language: English
  • Edition: Softcover Repri
  • Item Weight: 311 grams
  • BISAC Subject(s): Operations Research, Applied, and Biostatistics

From the Back Cover

Very little has been published on optimization of pharmaceutical portfolios. Moreover, most of the published literature comes from the commercial perspective, where probability of technical success (PoS) is treated as fixed, and not as a consequence of development strategy or design. In this book there is a strong focus on the impact of study design on PoS, and ultimately a portfolio's value. Design options that are discussed are dose-selection strategies, adaptive design, and enrichment. Some development strategies that are examined are indication sequencing, optimal number of programs, and optimal decision criteria.

This book includes chapters written by authors with very broad backgrounds including financial, clinical, statistical, decision sciences, commercial, and regulatory. Many authors have long held executive positions and have been involved with decision making at a product or at a portfolio level. As such, it is expected that this book will attract a very broad audience, including decision makers in pharmaceutical R&D, commercial, and financial departments. The intended audience also includes portfolio planners and managers, statisticians, decision scientists, and clinicians.

Early chapters describe approaches to portfolio optimization from big pharma, and venture capital standpoints, focusing on finances and processes. Later chapters present selected statistical and decision analysis methods for optimizing drug development programs and portfolios. Some methodological chapters are technical; however, with a few exceptions they require a basic knowledge of statistics by a reader.

Zoran Antonijevic is a Senior Director at Cytel Consulting with responsibility for strategic advice at trial, program, or portfolio level. His research areas include: adaptive design, pharmaceutical portfolio optimization, and decision-making within clinical drug development process. Zoran has 20 years of experience in drug development. His prior experience includes positions at Harvard School of Public Health, GlaxoSmithKline, and Quintiles Innovation where his primary responsibility was to develop designs and approaches that maximize probability of success for programs and/or maximize product's value. He also has extensive experience with performing due-diligence, and as a member of product portfolio executive teams. Externally, Zoran is the chair of DIA Adaptive Design Scientific Working Group.

Trusted for over 49 years

Family Owned Company

Secure Payment

All Major Credit Cards/Debit Cards/UPI & More Accepted

New & Authentic Products

India's Largest Distributor

Need Support?

Whatsapp Us